Unilever invests in advanced woundcare co:
This article was originally published in Clinica
Executive Summary
Georgia, Atlanta-based woundcare specialist Biofisica has closed a $5m series A financing round, led by Unilver Technology Ventures. Other participants in the round include Novartis Venture Fund, Advanced Technology Development Seed Capital Fund and existing investors. The funding will go towards the planned UK launch of Biofisica's POSiFECT RD bioelectric stimulation therapy, as well as to initial regulatory filings for US regulatory clearance, expansion of the company's workforce on both sides of the Atlantic and development of the product portfolio. The POSiFECT RD, CE-marked in October (see Clinica No 1230, p 18), is a moist woundcare dressing with electrical stimulation properties to manage difficult-to-heal or non-healing chronic wounds.